July 24, 2026

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400051 NSE Symbol: PANACEABIO	BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001 BSE Scrip Code: 531349

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

Dear Sir / Madam,

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform you that the Company's wholly owned subsidiary, Panacea Biotec Pharma Limited ("PBPL"), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax ("GST"), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ₹4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23.

The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed herewith as **Annexure A**.

This is for your kind information and record please.

Thanking you,
Sincerely yours,
For **Panacea Biotec Limited**

ANKIT JAIN Digitally signed by ANKIT JAIN Date: 2026.07.24 09:34:31 +05'30'

Ankit Jain
General Manager – Legal & Company Secretary

Annexure A

Details required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations

S. No.	Particulars	Details
1.	Name of the Listed Entity	Panacea Biotec Limited
2.	Type of communication received	The Company's wholly owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") has received a Show Cause Notice ('SCN') dated 23.07.2026 from Assistant Commissioner, GST, Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 ("Act")
3.	Date of receipt of communication	23.07.2026
4.	Authority from whom communication received	Assistant Commissioner, GST, Delhi
5.	Brief summary of the material contents of the communication received, including reasons for receipt of the communication	SCN dated 23.07.2026 has been issued alleging total tax liability of ₹4.06 Crore (comprising of tax ₹2.27 Crore, interest ₹1.56 Crore and penalty ₹0.23 Crore) on account of inter-alia, excess claim of ITC.
6.	Period for which communication would be applicable, if stated	Financial Year 2022-23
7.	Expected financial implications on the listed company, if any	PBPL is in the process of collating relevant details and preparing draft reply against the notice received. PBPL does not foresee any adverse impact on its financial, operational, or other activities arising from this SCN.
8.	Details of any aberrations/non-compliances identified by the authority in the communication	The Authority has alleged claim of excess ITC
9.	Details of any penalty or restriction or sanction imposed pursuant to the communication	Currently the matter is at SCN stage only.
10.	Action(s) taken by listed company with respect to the communication	PBPL is in the process of preparing response against the SCN.
11.	Any other relevant information	Not Applicable

ANKIT JAIN

Digitally signed by ANKIT JAIN
Date: 2026.07.24 09:35:17 +05'30'